What I learned at The Medtech Summit 2026
Notes from the sessions I sat in at The Medtech Summit in Berlin. These are my takeaways, not a transcript.
Risk management under the MDR and IVDR revisions
Speakers pushed for risk management that starts early in design and keeps going, led by evidence instead of fixed thresholds.
Post-market surveillance, complaints and open clinician feedback should feed the risk file continuously, not once a year. Reduced oversight could create safety blind spots.
Making real-world evidence useful
Registry quality and traceability decide how useful the data is. The advice was to combine registries with claims, device telemetry, structured field feedback and complaint systems.
Formalise how feedback comes in, so insights don't sit in informal reports. Regulators and payers want different evidence, so map both before designing a strategy.
Buying or building clinical evidence
Hospitals generally control the data they capture and patients have GDPR rights over it. Secondary use depends on the legal basis and ethics approval.
Outsourced or purchased data is still the manufacturer's responsibility, so vendors need proper scrutiny. Interoperability is improving, but European fragmentation isn't going away soon.
How much evidence is enough for high-risk devices
One notified body's framework weighs novelty, complexity, the quality and quantity of evidence, the state of the art, equivalence and early data on the device itself.
Randomised trials are the aspiration but not always appropriate. Registries and other designs can be justified. Post-market follow-up can't make up for thin evidence at certification, and talking to expert panels early can help.
Regulation moves quickly. Check the current position before relying on any of this.